The nirmatrelvir / ritonavir combination was studied in a randomized controlled trial of 2, 246 nonhospitalized symptomatic adults ≥ 18 years of age with a prespecified risk factor for progression to severe disease or ≥ 60 years of age regardless of prespecified chronic medical conditions.